Tricor is a drug owned by Abbvie Inc. It is protected by 9 US drug patents filed in 2013 out of which all have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Feb 21, 2023. Details of Tricor's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US7320802 | Methods of treatment using nanoparticulate fenofibrate compositions |
Feb, 2023
(1 year, 9 months ago) |
Expired
|
| US7276249 | Nanoparticulate fibrate formulations |
Feb, 2023
(1 year, 9 months ago) |
Expired
|
| US6375986 | Solid dose nanoparticulate compositions comprising a synergistic combination of a polymeric surface stabilizer and dioctyl sodium sulfosuccinate |
Sep, 2020
(4 years ago) |
Expired
|
| US7037529 | Fenofibrate pharmaceutical composition having high bioavailability and method for preparing it |
Jan, 2018
(6 years ago) |
Expired
|
| US6589552 | Fenofibrate pharmaceutical composition having high bioavailability and method for preparing it |
Jan, 2018
(6 years ago) |
Expired
|
| US7041319 | Fenofibrate pharmaceutical composition having high bioavailabilty |
Jan, 2018
(6 years ago) |
Expired
|
| US6652881 | Fenofibrate pharmaceutical composition having high bioavailability |
Jan, 2018
(6 years ago) |
Expired
|
| US6277405 | Fenofibrate pharmaceutical composition having high bioavailability and method for preparing it |
Jan, 2018
(6 years ago) |
Expired
|
| US6074670 | Fenofibrate pharmaceutical composition having high bioavailability and method for preparing it |
Jan, 2018
(6 years ago) |
Expired
|
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Tricor's patents.
Latest Legal Activities on Tricor's Patents
Given below is the list of recent legal activities going on the following patents of Tricor.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 12th Year, Large Entity | 22 Jul, 2019 | US7320802 (Litigated) |
| Payment of Maintenance Fee, 12th Year, Large Entity | 02 Apr, 2019 | US7276249 (Litigated) |
| Payment of Maintenance Fee, 12th Year, Large Entity | 16 Oct, 2017 | US7037529 (Litigated) |
| Payment of Maintenance Fee, 12th Year, Large Entity | 16 Oct, 2017 | US7041319 (Litigated) |
| File Marked Found | 18 Apr, 2016 | US6652881 |
| File Marked Found | 18 Apr, 2016 | US6589552 (Litigated) |
| File Marked Found | 07 Apr, 2016 | US6589552 (Litigated) |
| File Marked Found | 07 Apr, 2016 | US6652881 |
| File Marked Found | 05 Apr, 2016 | US6589552 (Litigated) |
| File Marked Found | 05 Apr, 2016 | US6652881 |
Several oppositions have been filed on Tricor's European patents. EP oppositions can significantly impact the timeline for the generic launch of drugs. If an opposition results in the revocation or amendment of a patent, it can shorten the exclusivity period of the original drug. This can lead to an earlier entry of generic versions into the market. To help you estimate the potential early arrival of Tricor's generic, the next section provides detailed information on ongoing and past EP oppositions related to Tricor patents.
Tricor's Oppositions Filed in EPO
Tricor has faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Jul 20, 2007, by Baxter Healthcare Corporation. This opposition was filed on patent number EP03723781A. Click below to reveal the latest opposition data.
| Application | Filing Date | Opposition Party | Legal Status |
|---|---|---|---|
 | |||
| EP03723781A | Jul, 2007 | Abraxis BioScience, Inc. | Patent maintained as amended |
| EP03723781A | Jul, 2007 | Baxter Healthcare Corporation | Patent maintained as amended |
US patents provide insights into the exclusivity only within the United States, but Tricor is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Tricor's family patents as well as insights into ongoing legal events on those patents.
Tricor's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Tricor's generic launch date based on the expiry of its last outstanding patent is estimated to be Feb 21, 2023 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Tricor Generic API suppliers:
Fenofibrate is the generic name for the brand Tricor. 33 different companies have already filed for the generic of Tricor, with Rising having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Tricor's generic
How can I launch a generic of Tricor before its drug patent expiration? :
You can seek FDA approval to launch a generic drug before the expiration of Tricor's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the Tricor's sponsor is invalid, unenforceable, or will not be infringed by your generic product.
Given below are the details of the already filed Para IV certificates on Tricor -
| Strength | Submission Date | ANDA(s) Filed | First applicant approval | Last patent expiry | 180 day status |
|---|---|---|---|---|---|
| 48 mg | 01 Jul, 2008 | 1 | 05 Apr, 2012 | 21 Feb, 2023 | Extinguished |
| 54 mg, 107 mg and 160 mg | |||||
| 145 mg | 19 Oct, 2007 | 1 | 21 Feb, 2023 | Extinguished |
Alternative Brands for Tricor
Tricor which is used for lowering cholesterol levels and treating hypertriglyceridemia., has several other brand drugs using the same active ingredient (Fenofibrate). Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | |
|---|---|---|
| Abbvie |
| |
| Cipher Pharms Inc |
| |
| Lupin |
| |
| Salix |
| |
| Skyepharma Ag |
|
Apart from brand drugs containing the same ingredient, some generics have also been filed for Fenofibrate, Tricor's active ingredient. Check the complete list of approved generic manufacturers for Tricor
About Tricor
Tricor is a drug owned by Abbvie Inc. It is used for lowering cholesterol levels and treating hypertriglyceridemia. Tricor uses Fenofibrate as an active ingredient. Tricor was launched by Abbvie in 2004.
Approval Date:
Tricor was approved by FDA for market use on 05 November, 2004.
Active Ingredient:
Tricor uses Fenofibrate as the active ingredient. Check out other Drugs and Companies using Fenofibrate ingredient
Treatment:
Tricor is used for lowering cholesterol levels and treating hypertriglyceridemia.
Dosage:
Tricor is available in tablet form for oral use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 48MG | TABLET | Discontinued | ORAL |
| 145MG | TABLET | Discontinued | ORAL |
| 54MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | TABLET | Discontinued | ORAL |
| 160MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | TABLET | Discontinued | ORAL |